share_log

Immatics Biotechnologies GmbH (NASDAQ:IMTXW) Sees Large Increase in Short Interest

Defense World ·  Apr 23, 2023 03:12

immatics biotechnologies GmbH (NASDAQ:IMTXW – Get Rating) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 17,400 shares, a growth of 6.1% from the March 15th total of 16,400 shares. Based on an average daily trading volume, of 5,900 shares, the days-to-cover ratio is presently 2.9 days.

immatics biotechnologies Price Performance

Shares of IMTXW stock opened at $1.53 on Friday. immatics biotechnologies has a twelve month low of $0.88 and a twelve month high of $4.41. The stock has a fifty day moving average price of $1.80.

Get immatics biotechnologies alerts:

Institutional Investors Weigh In On immatics biotechnologies

Several hedge funds have recently made changes to their positions in the company. Virtu Financial LLC purchased a new stake in shares of immatics biotechnologies during the 4th quarter worth $28,000. Jefferies Financial Group Inc. purchased a new stake in shares of immatics biotechnologies during the 4th quarter worth $80,000. Alyeska Investment Group L.P. purchased a new stake in shares of immatics biotechnologies during the 4th quarter worth $529,000. Finally, Aristeia Capital LLC lifted its stake in shares of immatics biotechnologies by 3,293.6% during the 4th quarter. Aristeia Capital LLC now owns 754,590 shares of the company's stock worth $1,856,000 after purchasing an additional 732,354 shares during the last quarter.

See Also

  • Get a free copy of the StockNews.com research report on immatics biotechnologies (IMTXW)
  • MarketBeat Week in Review – 4/17 – 4/21
  • 2 Industrial Strength Dividend Stocks Melting Up
  • Proctor & Gamble Is Going To Set A New High
  • AutoNation's Plans are Keeping Analysts Around
  • Netflix Increases Buybacks: Can It Complete A Reversal In 2023?

Receive News & Ratings for immatics biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for immatics biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment